View in EDS

Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases.

Saved in:
Bibliographic Details
Title: Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases.
Authors: Griffett K; Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States., Burris TP; The University of Florida Genetics Institute, Gainesville, FL, United States.
Source: Frontiers in medicine [Front Med (Lausanne)] 2023 Feb 02; Vol. 10, pp. 1102469. Date of Electronic Publication: 2023 Feb 02 (Print Publication: 2023).
Publication Type: Journal Article; Review
Journal Info: Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101648047 Publication Model: eCollection Cited Medium: Print ISSN: 2296-858X (Print) Linking ISSN: 2296858X NLM ISO Abbreviation: Front Med (Lausanne) Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36817797
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Griffett+K%22">Griffett K</searchLink>; Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States.<br /><searchLink fieldCode="AU" term="%22Burris+TP%22">Burris TP</searchLink>; The University of Florida Genetics Institute, Gainesville, FL, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101648047%22">Frontiers in medicine</searchLink> [Front Med (Lausanne)] 2023 Feb 02; Vol. 10, pp. 1102469. <i>Date of Electronic Publication: </i>2023 Feb 02 (<i>Print Publication: </i>2023).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Media+S%2EA%22">Frontiers Media S.A </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101648047 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2296-858X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222296858X%22">2296858X </searchLink><i>NLM ISO Abbreviation: </i>Front Med (Lausanne) <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36817797
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fmed.2023.1102469
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1102469
    Titles:
      – TitleFull: Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Griffett K
      – PersonEntity:
          Name:
            NameFull: Burris TP
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 02
              Text: 2023 Feb 02
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 2296-858X
          Numbering:
            – Type: volume
              Value: 10
          Titles:
            – TitleFull: Frontiers in medicine
              Type: main
ResultId 1